

Official title: Microfragmented Adipose Tissue Versus Platelet-rich Plasma for Knee Osteoarthritis: a Randomized Comparative Trial

NCT number: NCT04351087

Document date: March 30, 2023

1
2 **The Ohio State University Combined Consent to Participate in**
3 **Research and HIPAA Research Authorization**
4
5

Study Title: Adipose-derived stem cells versus platelet-rich plasma for knee osteoarthritis: a randomized comparative trial

Principal Investigator: Michael Baria, MD, MBA

Sponsor: The Ohio State University

- 6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
- **This is a consent form for research participation.** It contains important information about this study and what to expect if you decide to participate. Please consider the information carefully. Feel free to discuss the study with your friends and family and to ask questions before making your decision whether or not to participate.
 - **Your participation is voluntary.** You may refuse to participate in this study. If you decide to take part in the study, you may leave the study at any time. No matter what decision you make, there will be no penalty to you and you will not lose any of your usual benefits. Your decision will not affect your future relationship with The Ohio State University. If you are a student or employee at Ohio State, your decision will not affect your grades or employment status.
 - **You may or may not benefit as a result of participating in this study.** Also, as explained below, your participation may result in unintended or harmful effects for you that may be minor or may be serious depending on the nature of the research.
 - **You will be provided with any new information that develops during the study that may affect your decision whether or not to continue to participate.** If you decide to participate, you will be asked to sign this form and will receive a copy of the form. You are being asked to consider participating in this study for the reasons explained below.

26 **Key Information About This Study**

27 The following is a short summary to help you decide whether or not to be a part of this study.
28 More detailed information is listed later in this form.

29
30 Two new treatments for knee arthritis are platelet-rich plasma (PRP) and adipose (fat) derived
31 stem cells (ADSC). However, no study has ever compared them to see if one is better. This
32 study will randomize participants to receive one of these treatments and follow clinical
33 outcomes for 1 year to determine if one of these treatments is superior.

34
35 **1. Why is this study being done?**
36

37 This study is being conducted to compare two treatments (adipose-derived stem cells
38 [ADSC] and platelet-rich plasma [PRP]) for knee arthritis. Both are derived from your
39 own body and are currently used to treat knee arthritis, but they have never been
40 compared. Our goal is to analyze how effective they are and how they compare to each
41 other.

42
43

44 **2. How many people will take part in this study?**

45

46 110 participants with knee arthritis

47

48

49 **3. What will happen if I take part in this study?**

50

51 You are being asked to participate in this research study because you have knee arthritis.
52 If you choose to participate, you will be randomized to receive 1 injection of either ADSC
53 or PRP. This means that a computer will randomly assign you to one treatment or the
54 other. There is an equal chance of getting each treatment. Participants and doctors have
55 no influence over which group you are assigned. PRP is considered the standard
56 treatment and the ADSC is considered the experimental arm.

57

58 For the ADSC injection, you will have a small amount (30ml; approximately 6 teaspoons)
59 of fat taken from your abdomen, buttock or thigh. The area will be numbed using a local
60 anesthetic. A needle will be used to remove the fat. The fat is then processed to remove
61 oil and blood and liquefy the remaining contents from the fat. This will be done in the
62 office and all in one visit. This will then be injected back into your knee. A small amount
63 (<1ml) will be sent to an Ohio State laboratory to count the number of stem cells.

64

65 For the PRP injection, you will have 157mL (about 31 teaspoons) of blood drawn from
66 your arm. This blood will be put into a centrifuge that will spin down the blood and pull
67 out the PRP. The PRP will then be injected into your knee. A small amount (<1ml) of
68 your whole blood and PRP will be analyzed in sports medicine to count the number of
69 platelets in your blood and PRP. That same PRP sample will be analyzed for growth
70 factors (proteins that can help tissue heal).

71

72 At the time of the injection, if your knee has excess fluid, this fluid will be removed prior
73 to injecting the ADSC or PRP. We will analyze this fluid with a complete blood count
74 and examination for inflammatory proteins.

75

76 Both procedures will take between 60-90 minutes.

77

78 You will be asked to fill out surveys about your knee pain before the injection and then at
79 1,3,6 and 12 months. Additionally, if you receive the ADSC injection, your doctor will
80 see you 2 weeks after the injection to make sure the aspiration site looks healthy. All
81 injections and follow up visits are covered by the research fund and your insurance will

82 not be billed. If you have had a knee MRI in the last year, your doctors will also look at it
83 to judge the severity of arthritis.

84

85 **4. How long will I be in the study?**

86

87 1 year.

88

89 **5. Can I stop being in the study?**

90

91 You may leave the study at any time. If you decide to stop participating in the study,
92 there will be no penalty to you, and you will not lose any benefits to which you are
93 otherwise entitled. Your decision will not affect your future relationship with The Ohio
94 State University.

95

96

97 **6. What risks, side effects or discomforts can I expect from being in the study?**

98 The possible risks associated with participating in this research project are related to taking
99 the fat or blood, and from the knee injection. From taking the fat, risks include bruising,
100 bleeding, pain, swelling, infection and creating a dimple in the skin where the fat was taken
101 from. For the PRP blood draw risks include pain, bleeding, infection, fainting, bruising.

102

103 From the knee injection, risks include pain at the injection site, redness, a brief increase in
104 joint pain or swelling, and infection.

105

106 There is also the risk of breach of confidentiality. Specimens and data will be labeled as a
107 numerical code. Your name will only be recorded on this document. No other link to you
108 and your blood / fat sample will exist.

109

110 **7. What benefits can I expect from being in the study?**

111

112 There will be no direct benefits to you.

113

114 **8. What other choices do I have if I do not take part in the study?**

115

116 You may choose not to participate without penalty or loss of benefits to which you are
117 otherwise entitled. The PRP is available outside of this study; it is an out of pocket
118 expense as it is not covered by insurance. The ADSC is not available outside this study.

119

120 **9. What are the costs of taking part in this study?**

121

122 There are no costs in taking part of this study. Parking is free at both the Jameson Crane
123 Sports Medicine Institute and the Sports Medicine clinic located at Lewis Center. You will
124 be financially responsible for all costs associated with treatment for all complications
125 resulting from the procedure.

126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169

10. Will I be paid for taking part in this study?

You will receive a 20 dollar Amazon gift card at the injection and the 1, 3, 6, and 12 month visit. By law, payments to participants are considered taxable income.

11. What happens if I am injured because I took part in this study?

If you suffer an injury from participating in this study, you should notify the researcher or study doctor immediately, who will determine if you should obtain medical treatment at The Ohio State University Wexner Medical Center.

The cost for this treatment will be billed to you or your medical or hospital insurance. The Ohio State University has no funds set aside for the payment of health care expenses for this study.

12. What are my rights if I take part in this study?

If you choose to participate in the study, you may discontinue participation at any time without penalty or loss of benefits. By signing this form, you do not give up any personal legal rights you may have as a participant in this study.

You will be provided with any new information that develops during the course of the research that may affect your decision whether or not to continue participation in the study.

You may refuse to participate in this study without penalty or loss of benefits to which you are otherwise entitled.

An Institutional Review Board responsible for human subjects research at The Ohio State University reviewed this research project and found it to be acceptable, according to applicable state and federal regulations and University policies designed to protect the rights and welfare of participants in research.

13. Will my de-identified information and bio-specimens be used or shared for future research?

No.

14. Will my study-related information be kept confidential?

170 Efforts will be made to keep your study-related information confidential. However, there
171 may be circumstances where this information must be released. For example, personal
172 information regarding your participation in this study may be disclosed if required by state
173 law.

174
175 Also, your records may be reviewed by the following groups (as applicable to the
176 research):

- 177 • Office for Human Research Protections or other federal, state, or international
178 regulatory agencies;
- 179 • U.S. Food and Drug Administration;
- 180 • The Ohio State University Institutional Review Board or Office of Responsible
181 Research Practices;
- 182 • The sponsor supporting the study, their agents or study monitors; and
- 183 • Your insurance company (if charges are billed to insurance).

184
185 If this study is related to your medical care, your study-related information may be placed
186 in your permanent hospital, clinic, or physician's office records. Authorized Ohio State
187 University staff not involved in the study may be aware that you are participating in a
188 research study and have access to your information.

189
190 Your name will not appear on any of those specimens and your participation will remain
191 confidential. Specimens and data will be labeled with a numerical code.

192
193
194 **15. HIPAA AUTHORIZATION TO USE AND DISCLOSE INFORMATION FOR**
195 **RESEARCH PURPOSES**

196
197 **I. What information may be used and given to others?**

- 198
- 199 • Past and present medical records;
- 200 • Research records;
- 201 • Records about phone calls made as part of this research;
- 202 • Records about your study visits;
- 203 • Information that includes personal identifiers, such as your name, or a number
204 associated with you as an individual;

205
206 **II. Who may use and give out information about you?**

207
208 Researchers and study staff.

209
210 **III. Who might get this information?**

- 211
- 212 • The sponsor of this research. "Sponsor" means any persons or companies that are:
213 • working for or with the sponsor; or

- 214 • owned by the sponsor.
- 215 • Authorized Ohio State University staff not involved in the study may be aware that
- 216 you are participating in a research study and have access to your information;
- 217 • If this study is related to your medical care, your study-related information may be
- 218 placed in your permanent hospital, clinic, or physician's office record;
- 219

220 **IV. Your information may be given to:**

221

- 222 • The U.S. Food and Drug Administration (FDA), Department of Health and Human
- 223 Services (DHHS) agencies, and other federal and state entities;
- 224 • Governmental agencies in other countries;
- 225 • Governmental agencies to whom certain diseases (reportable diseases) must be
- 226 reported; and
- 227 • The Ohio State University units involved in managing and approving the research
- 228 study including the Office of Research and the Office of Responsible Research
- 229 Practices.
- 230

231 **V. Why will this information be used and/or given to others?**

232

- 233 • To do the research;
- 234 • To study the results; and
- 235 • To make sure that the research was done right.
- 236

237 **VI. When will my permission end?**

238

239 There is no date at which your permission ends. Your information will be used

240 indefinitely. This is because the information used and created during the study may be

241 analyzed for many years, and it is not possible to know when this will be complete.

242

243 **VII. May I withdraw or revoke (cancel) my permission?**

244

245 Yes. Your authorization will be good for the time period indicated above unless you

246 change your mind and revoke it in writing. You may withdraw or take away your

247 permission to use and disclose your health information at any time. You do this by

248 sending written notice to the researchers. If you withdraw your permission, you will not

249 be able to stay in this study. When you withdraw your permission, no new health

250 information identifying you will be gathered after that date. Information that has already

251 been gathered may still be used and given to others.

252

253 **VIII. What if I decide not to give permission to use and give out my health**

254 **information?**

255

256 Then you will not be able to be in this research study and receive research-related
257 treatment. However, if you are being treated as a patient here, you will still be able to
258 receive care.

259
260 **IX. Is my health information protected after it has been given to others?**

261
262 There is a risk that your information will be given to others without your permission. Any
263 information that is shared may no longer be protected by federal privacy rules.

264
265 **X. May I review or copy my information?**

266
267 Signing this authorization also means that you may not be able to see or copy your study-
268 related information until the study is completed.

269
270
271 **16. Who can answer my questions about the study?**

272
273 For questions, concerns, or complaints about the study you may contact *Dr. Michael*
274 *Baria at Michael.baria@osumc.edu or (614) 366-9324.*

275
276 For questions about your rights as a participant in this study or to discuss other study-
277 related concerns or complaints with someone who is not part of the research team, you
278 may contact Ms. Sandra Meadows in the Office of Responsible Research Practices at 1-
279 800-678-6251.

280
281 If you are injured as a result of participating in this study or for questions about a study-
282 related injury, you may contact *Dr. Michael Baria at Michael.baria@osumc.edu or (614)*
283 *366-9324.*

284
285
286
287 **Signing the consent form**

288
289 I have read (or someone has read to me) this form and I am aware that I am being asked to
290 participate in a research study. I have had the opportunity to ask questions and have had them
291 answered to my satisfaction. I voluntarily agree to participate in this study.

292
293 I am not giving up any legal rights by signing this form. I will be given a copy of this form.
294

Printed name of subject

Signature of subject

Date and time

AM/PM

Printed name of person authorized to consent for subject
(when applicable)

Signature of person authorized to consent for subject
(when applicable)

Relationship to the subject

Date and time

AM/PM

295
296
297
298
299
300
301
302
303

Investigator/Research Staff

I have explained the research to the participant or his/her representative before requesting the signature(s) above. There are no blanks in this document. A copy of this form has been given to the participant or his/her representative.

Printed name of person obtaining consent

Signature of person obtaining consent

Date and time

AM/PM

304
305
306
307

Witness(es) - *May be left blank if not required by the IRB*

Printed name of witness

Signature of witness

Date and time

AM/PM

Printed name of witness

Signature of witness

Date and time

AM/PM

308
309